ConductScience.org, home

Paper413551

In vitro studies with hexamethylmelamine.

Rutty CJ and 1 other. Biochem Pharmacol, 1977. Cited by 82 papers, by iCite.

Cite this record

ConductScience Library. In vitro studies with hexamethylmelamine. Papers, record 413551. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/413551

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro studies with hexamethylmelamine.
PubMed
Journal
Biochem Pharmacol
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
82
iCite
Relative citation ratio, by iCite
4.28
iCite
Revised in PubMed
2019-06-23
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rutty CJC J
2Connors TAT A

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AltretamineMajor topic
TriazinesMajor topic
Animals
Antineoplastic Agents
Chromatography, Thin Layer
Dealkylation
Female
In Vitro Techniques
Mice
Mice, Inbred BALB C
Microsomes, Liver
Rats
Structure-Activity Relationship

Source PubMed

Download CSV of topics

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 82 citations.

PMIDTitleJournalYearIn PapersSource
7656502Clinical pharmacokinetics of altretamine.Clin Pharmacokinet1995https://conductscience.org/library/papers/7656502PubMed
7641606Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.Drugs1995https://conductscience.org/library/papers/7641606PubMed
7272193British Association for Cancer Research 22nd Annual general meeting. 13-15 April 1981. Abstracts.Br J Cancer1981https://conductscience.org/library/papers/7272193PubMed
7126433The British Association for Cancer Research, 23rd annual general meeting. Edinburgh 29--31 March 1982. Abstracts.Br J Cancer1982https://conductscience.org/library/papers/7126433PubMed
6994913The practical benefits of pharmacokinetics in the use of antineoplastic agents.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/6994913PubMed
6808457Hexamethylmelamine and hexamethylmelamine hydrochloride.Pharm Weekbl Sci1982https://conductscience.org/library/papers/6808457PubMed
6807560The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6807560PubMed
6794923Dose-dependent pharmacokinetics of PMM in the rat.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/6794923PubMed
6791675In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.Br J Cancer1981https://conductscience.org/library/papers/6791675PubMed
6770884Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.Br J Cancer1980https://conductscience.org/library/papers/6770884PubMed
6432969Human central nervous system pharmacology of pentamethylmelamine and its metabolites.J Neurooncol1983https://conductscience.org/library/papers/6432969PubMed
6401427Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.Br J Cancer1983https://conductscience.org/library/papers/6401427PubMed
3924426Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3924426PubMed
3552281N-methyl antitumour agents. A distinct class of anticancer drugs?Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3552281PubMed
3100080Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3100080PubMed
3091280
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.
Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3091280PubMed
3087399Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.Br J Cancer1986https://conductscience.org/library/papers/3087399PubMed
1997112Phase II trial of trimelamol in refractory ovarian cancer.Br J Cancer1991https://conductscience.org/library/papers/1997112PubMed
508562Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.Br J Cancer1979https://conductscience.org/library/papers/508562PubMed
475962Assays of drug sensitivity for cells from human tumours: in vitro and in vivo tests on a xenografted tumour.Br J Cancer1979https://conductscience.org/library/papers/475962PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/413551

GET https://conductscience.org/api/papers/v1/413551/cited_by?page=2